Characterization of a mutant estrogen receptor in an MCF-7 cell line
Author Information
Author(s): JJ Pink, M Fritsch, MM Bilimoria, VJ Assikis, VC Jordan
Primary Institution: University of Wisconsin Comprehensive Cancer Center; Northwestern University Medical School
Hypothesis
The study investigates the role of a mutant estrogen receptor (ER77) in the development of estrogen-independent growth in breast cancer cells.
Conclusion
The mutant ER77 does not bind ligands and inhibits the activity of the wild-type estrogen receptor, suggesting it does not promote estrogen-independent growth.
Supporting Evidence
- The mutant ER77 was found to have a tandem duplication of exons 6 and 7.
- ER77 does not bind to ligands like estradiol or tamoxifen.
- ER77 inhibits the transcriptional activity of the wild-type ER in transfection assays.
- MCF-7:2A cells expressing ER77 showed estrogen-independent growth characteristics.
Takeaway
Researchers found a new version of an estrogen receptor that doesn't work like the normal one and can stop the normal one from doing its job, which might help explain why some breast cancer cells grow without estrogen.
Methodology
The study involved cloning and sequencing the mutant estrogen receptor, along with various assays to test ligand binding, DNA binding, and transcriptional activity.
Limitations
The study does not explore all potential pathways involved in estrogen-independent growth and focuses primarily on the ER77 receptor.
Participant Demographics
The study used human breast cancer cell lines, specifically MCF-7 and its subclones.
Want to read the original?
Access the complete publication on the publisher's website